NA - Listed on 25 June 2026
Avience Biomedicals (NA) closed its IPO window in 2026 and listed on NSE and BSE on 25 June 2026 for a listing gain of +99.5% (+99.5% on closing basis). The IPO was subscribed - overall - QIB -, HNI/NII -, Retail -. The total issue size was available on this page. IPO GMP data, subscription trends across Day 1 - Day 3 and Nifty performance around the listing window are detailed below.
NA
Avience Biomedicals operates in the NA space. The company’s listed profile is shaped by its operating niche, customer demand and ability to convert that demand into steady cash flows. Investors should read its exchange filings alongside the headline listing numbers for a fuller view of the business.
Issue structure, listing outcome and context
The Avience Biomedicals issue was offered at an upper price of - and raised approximately - crore. The final outcome reflected a mix of subscription demand, valuation, market conditions and the company’s own operating story. Fresh issue and offer-for-sale details, where available, are shown in the issue metrics below.
Number of times each investor category subscribed by close of Day 3.
How overall subscription built up across the three-day issue window.
Grey market premium (GMP) tracked day-by-day across the IPO window. Absolute GMP is the premium in rupees over the upper issue price; GMP % is that premium as a percent of the issue price.
| Day | GMP (Rs) | GMP % |
|---|---|---|
| Day 1 | - | - |
| Day 2 | - | - |
| Day 3 | - | - |
| Day 4 | - | - |
| Day 5 | - | - |
How the broader market moved around the Avience Biomedicals IPO window. Helpful for isolating how much of the listing gain came from company fundamentals vs. market tailwind.
Avience Biomedicals IPO listed at +99.5% versus the upper issue price of - on 25 June 2026.
Subscription data is listed in the Subscription breakdown section above.
Day-by-day IPO GMP data for Avience Biomedicals is listed in the table above.